Essenlix has developed the iMOST (Instant Mobile Self-Test) platform, which revolutionizes the way health diagnostics are conducted by enabling individuals to perform tests on themselves using a small sample of body fluid. This innovative technology allows for accurate health assessments to be conducted anywhere and at any time, utilizing a handheld device that can be smartphone-based. The iMOST platform is designed to be fault-tolerant, ensuring that it can deliver clinical lab-quality results even when there are imperfections in the sample or testing process. It supports a wide range of sample types, including blood, saliva, and urine, and can conduct various assays, such as immunoassays and nucleic acid tests, making it a versatile tool for personal health monitoring.

The iMOST platform incorporates advanced technologies such as nanotechnology, advanced imaging, and Nano-Enabled Artificial Intelligence/Machine Learning (NEAM) to enhance its diagnostic capabilities. By moving away from traditional lab testing paradigms, which require complex machinery and professional oversight, Essenlix has created a user-friendly system that is both cost-effective and efficient. The iMOST reader, paired with a proprietary app, allows users to receive test results within minutes, facilitating immediate communication with healthcare providers. This approach not only streamlines the testing process but also aims to make health diagnostics accessible to a broader population, addressing significant barriers in digital health.

United States

Essenlix Corporation is a fast-growing startup company in Princeton that develops a new easy-to-use, ultrasensitive, fast, assay platform for life science, diagnostics, and personal health.

Essenlix

Company Details